Collegium Pharmaceutical Inc Asset Resilience Ratio
Collegium Pharmaceutical Inc asset resilience ratio. Collegium Pharmaceutical Inc (COLL) has an Asset Resilience Ratio of 8.45% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Collegium Pharmaceutical Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Collegium Pharmaceutical Inc (2015–2024)
Asset resilience ratio of Collegium Pharmaceutical Inc from 2015 to 2024. This chart shows how Collegium Pharmaceutical Inc's Asset Resilience Ratio has changed over time. Read Collegium Pharmaceutical Inc (COLL) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Collegium Pharmaceutical Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see COLL total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $135.77 Million | 8.45% |
| Total Liquid Assets | $135.77 Million | 8.45% |
Asset Resilience Insights
- Limited Liquidity: Collegium Pharmaceutical Inc maintains only 8.45% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Collegium Pharmaceutical Inc Industry Peers by Asset Resilience Ratio
Compare Collegium Pharmaceutical Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Collegium Pharmaceutical Inc Asset Resilience Ratio by Year (2015–2024)
Collegium Pharmaceutical Inc asset resilience ratio by year from 2015 to 2024. The table below shows the annual Asset Resilience Ratio data for Collegium Pharmaceutical Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 5.54% | $92.20 Million | $1.66 Billion | -0.72pp |
| 2023-12-31 | 6.26% | $71.60 Million | $1.14 Billion | -- |
| 2022-12-31 | 0.00% | $0.00 | $1.17 Billion | -- |
| 2017-12-31 | 0.00% | $0.00 | $135.57 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $162.02 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $97.72 Million | -- |
About Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine… Read more